Ibritumomab Tiuxetan - Cancer Science

Relevant Publications

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.

Issue Release: 2024

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin\'s lymphoma.

Issue Release: 2024

The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.

Issue Release: 2024

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin\'s Lymphoma.

Issue Release: 2023

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.

Issue Release: 2023

Theranostics in Hematooncology.

Issue Release: 2023

Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.

Issue Release: 2023

Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin\'s lymphoma: J3Zi Study.

Issue Release: 2023

Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.

Issue Release: 2023

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.

Issue Release: 2022

Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting.

Issue Release: 2022

Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Issue Release: 2022

A bibliometric analysis for relapsed/refractory Non-Hodgkin lymphoma.

Issue Release: 2022

Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.

Issue Release: 2022

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.

Issue Release: 2022

Immunotherapy in indolent Non-Hodgkin\'s Lymphoma.

Issue Release: 2022

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.

Issue Release: 2021

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

Issue Release: 2021

A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.

Issue Release: 2021

Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma.

Issue Release: 2021

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Ibritumomab Tiuxetan - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics